Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|June 10, 2021

Ushering in the Golden Era of Alzheimer Drug Development?

Author(s)RJ Tesi, MD

What effect will aducanumab have on Alzheimer disease treatment?

RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.

Dr Tesi is CEO and Chief Medical Officer of INmuneBio.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

benzodiazepine

Podcast: How to Mindfully Prescribe Benzodiazepines With Carl Salzman, MD

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 28th 2026

Jchanism/Adobe Stock

Modified Titration Dosing Reduces ARIA-E Risk With Donanemab, A Discussion With John Sims, MD

ByJessica Walters,John Sims, MD

August 28th 2026

catalin/Adobe Stock

Diagnosing and Treating Alzheimer Disease: August's Key Developments

ByJessica Walters

August 27th 2026

ipopba/Adobe Stock

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data

ByAnthony Sireci, MD,Jessica Walters

August 27th 2026

Felix/peopleimages.com/Adobe Stock

Benzodiazepines in Older Adults: Alzheimer Risk, Memory, and Beers Criteria

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 26th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know